The efficacy of magnesium oxide and sodium valproate in prevention of migraine headache: a randomized, controlled, double-blind, crossover study (original) (raw)

Abstract

Migraine is a disabling disorder that affects the quality of life of patients. Different medications have been used in prevention of migraine headache. In this study, we evaluated the effectiveness of magnesium oxide in comparison with valproate sodium in preventing migraine headache attacks. This is a single-center, randomized, controlled, crossover trial which is double-blind, 24-week, 2-sequence, 2-period, 2-treatment. After patient randomization into two sequences, the intervention group received magnesium oxide 500 mg and the control group received valproate sodium 400 mg two tablets each day (every 12 h) for 8 weeks. The primary efficacy variable was reduction in the number of migraine attacks and number of days with moderate or severe headache and hours with headache (duration) per month in the final of 8 weeks in comparison with baseline. Seventy patients were randomized and seven dropped out, leaving 63 for analysis. In an intention-to-treat analysis, 31 patients were in group 1 (magnesium oxide–valproate) and 32 patients were in group 2 (valproate–magnesium oxide). The mean number of migraine attacks and days per month was 1.72 ± 1.18 and 2.09 ± 1.70, with a mean duration of 15.50 ± 21.80 h in magnesium group and 1.27 ± 1.27 and 2.22 ± 1.96, with a mean duration 13.38 ± 14.10 in valproate group. This study has shown that 500 mg magnesium oxide appears to be effective in migraine prophylaxis similar to valproate sodium without significant adverse effect.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Martin VT, Behbehani MM (2001) Towards a rational understanding of migraine trigger factors. Med Clin N Am 85:911–941
    Article CAS Google Scholar
  2. Lipton RB, Liberman JN, Kolodner KB, igal ME, Dowson A, Stewart WF (2003) Migraine headache disability and health-related quality-of-life: a population-based case-control study from England. Cephalalgia 23:441–450
    Article CAS Google Scholar
  3. Stewart WF, Shechter A, Rasmussen BK (1994) Migraine prevalence. A review of population-based studies. Neurology 44 (6 Suppl 4):S17–S23
    CAS PubMed Google Scholar
  4. Shahbeigi S, Fereshtehnejad SM, Mohammadi N et al (2013) Epidemiology of headaches in Tehran urban area: a population based cross-sectional study in district 8, year 2010. Neurol Sci 34:1157–1166
    Article Google Scholar
  5. Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V. Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study. Headache 2006;46:642–648
    Article Google Scholar
  6. Karimi N, Tavakoli M, Yazdani Charati J, Shamsizade M (2017) Single-dose intravenous sodium valproate (Depakine) versus dexamethasone for the treatment of acute migraine headache: a doubleblind randomized clinical trial. Clin Exp Emerg Med 4 (2):1–8
    Google Scholar
  7. Rybicka M, Baranowska-Bosiacka I, Żyluk B, Nowacki P, Chlubek D (2012) The role of magnesium in migraine pathogenesis. Potential use of magnesium compounds in prevention and treatment of migraine headaches. J Elementol 17:345–356
    Google Scholar
  8. Welch KM, Ramadan NM (1995) Mitochondria, magnesium and migraine. J Nneurol Sci 134:9–14
    Article CAS Google Scholar
  9. Schoenen J, Sianard -Gainko J, Lenaerts M (1991) Blood magnesium levels in migraine. Cephalalgia 11:97–99
    Article CAS Google Scholar
  10. Facchinetti F, Sances G, Borella P, Genazzani AR, Nappi G (1991) Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache 31:298–301 24
    Article CAS Google Scholar
  11. Baudouin-Legros M, Dard B, Guichency P (1986) Hyperreactivity of platelets from spontaneously hypertensive rats. Role of external magnesium. Hypertension 8:694–699
    Article CAS Google Scholar
  12. Altura BT, Altura BM (1989) Withdrawal of magnesium causes vasospasm while elevated magnesium produced relaxation of tone in cerebral arteries. Neurosci Lett 20:323–327
    Article Google Scholar
  13. Weglicki WB, Phillips TM (1992) Pathobiology of magnesium deficiency: a cytokine/neurogenic inflammation hypothesis. Am J Physiol 263:R734–R737
    CAS PubMed Google Scholar
  14. Choi H, Parmar N (2014) The use of intravenous magnesium sulphate for acute migraine: meta-analysis of randomized controlled trials. Eur J Emerg Med 21:2–9
    PubMed Google Scholar
  15. Peikert A, Wilimzig C, Köhne-Volland F (1996) Prophylaxis of migraine with oral magnesium: results from a prospective, multicenter, placebo-controlled and double-blind randomized study. Cephalalgia 16:257–263
    Article CAS Google Scholar
  16. Pfaffenrath V, Wessely P, Meyer C, Isler HR, Evers S, Grotemeyer KH, Taner Z, Soycal D, G’bell H, Fischer M (1996) Magnesium in the prophylaxis of migraine—a double-blind, placebo-controlled study. Cephalalgia 16:436–440
    Article CAS Google Scholar
  17. Koseoglu E, Talashoglu A, Gonul AS, Kula M (2008) The effects of magnesium prophylaxis in migraine without aura. Magnes Res 21:101–108
    CAS PubMed Google Scholar
  18. Maizels M, Blumenfeld A, Burchette R (2004) A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache 44:885–890
    Article Google Scholar
  19. Zhou Y, Gao L (1998) Flunarizine combined with magnesium polarization liquid on treating refractory migraine. Clin Focus 13:664
    Google Scholar
  20. Hu CS, Zhou LB (2011) Observation of clinical effects of magnesium valproate combined with venlafaxine HCl in 54 individuals with migraine. China Mod Med 18:62
    Google Scholar
  21. Bian X, Zhu Y, Xia J, Ai HJ, Guo QY, Lu LB, Zhang QW (2013) Clinical observation om potassium magnesium asparate oral soluation combined with flinarizine capsule for migraine prophylaxis. J Comm Med 11:6–7
    CAS Google Scholar
  22. Tang XY, Lin WZ, Zheng XM, Liu CS (1998) Observation of effects of nimodipine and magnesium sulfate combination for treating migraine. J Qiqihar Med Coll 19:5–6
    Google Scholar
  23. Alghadeer SM (2016) The efficacy of different oral magnesium supplements for migraine prevention: a literature review. Indones J Pharm 27 (3):174–182
    Article CAS Google Scholar
  24. Chiu HY, Yeh TH, Huang YC, Chen PY (2016) Effects of intravenous and oral magnesium on reducing migraine: a meta-analysis of randomized controlled trials. Pain Physician 19:E97–E112
    PubMed Google Scholar
  25. Pringsheim T, Davenport W, Mackie G et al (2012) Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci 39:S1–S59
    Article Google Scholar
  26. Teigen L, Boes ChJ (2015) An evidence-based review of oral magnesium supplementation in the preventive treatment of migraine. Cephalalgia 35 (10):912–922
    Article Google Scholar
  27. Hering R, Kuritzky A (1992) Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 12:81–84
    Article CAS Google Scholar
  28. International Headache Society Committee on Clinical Trials in Migraine (2012) Guidelines for controlled trials of drugs in migraine. Third edition. A guide for investigators. Cephalalgia 32 (1):6–38
    Article Google Scholar
  29. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edn (beta version). Cephalalgia 2013; 33:629–808
    Article Google Scholar
  30. Bayliss MS, Dewey JE, Dunlap I, Batenhorst AS, Cady R, Diamond ML, Sheftell F (2003 Dec) A study of the feasibility of Internet administration of a computerized health survey: the headache impact test (HIT). Qual Life Res 12 (8):953–961
    Article CAS Google Scholar
  31. Stewart WF, Lipton RB, Kolodner K (2003) Migraine disability assessment (MIDAS) score: relation to headache frequency, pain intensity, and headache symptoms. Headache 43 (3):258–265
    Article Google Scholar
  32. Ghorbani A, Chitsaz A (2011) Comparison of validity and reliability of the migraine disability assessment (MIDAS) versus headache impact test (HIT) in an Iranian population. Iran J Neurol 10:39–42
    PubMed PubMed Central Google Scholar
  33. Wang F, Van Den Eeden SK, Ackerson LM, Salk SE, Reince RH, Elin RJ (2003) Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache 43 (6):601–610
    Article Google Scholar
  34. Tarighat Esfanjani A, Mahdavi R, Ebrahimi Mameghani M, Talebi M, Nikniaz Z, Safaiyan A (2012) The effects of magnesium, l-carnitine, and concurrent magnesium-l-carnitine supplementation in migraine prophylaxis. Biol Trace Elem Res 150 (1–3):42–48
    Article Google Scholar
  35. Gaul C, Diener H-C, Danesch U (2015) Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. J Headache Pain 16 (1):32
    Article Google Scholar
  36. Demirkaya S, Dora B, Topcuoglu MA, Vural O, U HU (2001) A comparative study of magnesium, flunarizine and amitriptyline in the prophylaxis of migraine. J Headache Pain 1 (2000):179–186
    Google Scholar
  37. Mauskop A, Altura BT, Altura BM (2002) Serum ionized magnesium levels and serum ionized calcium/ionized magnesium ratios in women with menstrual migraine. Headache 42:242–248
    Article Google Scholar
  38. Abraham GE, Lubran MM (1981) Serum and red cell magnesium levels in patients with premenstrual tension. Am J Clin Nutr 34 (11):2364–2366
    Article CAS Google Scholar

Download references

Acknowledgements

The authors wish to thank all the patients who participated in this study and Alimohammady pharmacy due to providing drugs and the Research Vice-Chancellor of Maznadaran University of Medical Sciences for their financial supports and also Clinical Research Development Unit of Bou Ali Sina Hospital to approve this proposal.

Author information

Authors and Affiliations

  1. School of Medicine, Immunogenetics Research Center, Clinical Research Development Unit of Bou Ali Sina Hospital, Mazandaran University of Medical Sciences, Pasdaran boulevard, Sari, Mazandaran Province, Iran
    Narges Karimi
  2. Mazandarn University of Medical Sciences, Sari, Iran
    Azadeh Razian
  3. Department of Epidemiology and Biostatistics, School Of Medicine, Urmia University of Medical Sciences, Urmia, Iran
    Mohammad Heidari

Authors

  1. Narges Karimi
    You can also search for this author inPubMed Google Scholar
  2. Azadeh Razian
    You can also search for this author inPubMed Google Scholar
  3. Mohammad Heidari
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toNarges Karimi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

About this article

Cite this article

Karimi, N., Razian, A. & Heidari, M. The efficacy of magnesium oxide and sodium valproate in prevention of migraine headache: a randomized, controlled, double-blind, crossover study.Acta Neurol Belg 121, 167–173 (2021). https://doi.org/10.1007/s13760-019-01101-x

Download citation

Keywords